CREDIT SUISSE AG/ - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 152 filers reported holding REVANCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.06 and the average weighting 0.2%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,612,854
-55.2%
140,615
-1.1%
0.00%
-50.0%
Q2 2023$3,598,778
-19.5%
142,188
+2.4%
0.00%
-20.0%
Q1 2023$4,472,229
+86.4%
138,846
+6.8%
0.01%
+66.7%
Q4 2022$2,399,892
-8.6%
130,005
+33.7%
0.00%0.0%
Q3 2022$2,625,000
+109.2%
97,253
+7.0%
0.00%
+200.0%
Q2 2022$1,255,000
-29.0%
90,877
+0.2%
0.00%
-50.0%
Q1 2022$1,767,000
+27.4%
90,653
+6.7%
0.00%
+100.0%
Q4 2021$1,387,000
-42.2%
84,970
-1.3%
0.00%0.0%
Q3 2021$2,398,000
-1.7%
86,056
+4.6%
0.00%0.0%
Q2 2021$2,440,000
+1.6%
82,295
-4.2%
0.00%0.0%
Q1 2021$2,401,000
-21.2%
85,902
-20.1%
0.00%0.0%
Q4 2020$3,047,000
+114.9%
107,500
+90.6%
0.00%0.0%
Q3 2020$1,418,000
+17.4%
56,391
+14.0%
0.00%0.0%
Q2 2020$1,208,000
+37.1%
49,464
-16.9%
0.00%0.0%
Q1 2020$881,000
+55.1%
59,540
+70.1%
0.00%
Q4 2019$568,000
+61.4%
35,012
+29.5%
0.00%
Q3 2019$352,000
-6.4%
27,045
-6.8%
0.00%
Q2 2019$376,000
+0.8%
29,007
+22.8%
0.00%
Q1 2019$373,000
-6.3%
23,629
+19.5%
0.00%
Q4 2018$398,000
-7.7%
19,780
+14.2%
0.00%
Q3 2018$431,000
-36.8%
17,318
-30.2%
0.00%
-100.0%
Q2 2018$682,000
-13.5%
24,809
-3.0%
0.00%0.0%
Q1 2018$788,000
-21.4%
25,575
-8.9%
0.00%0.0%
Q4 2017$1,002,000
+49.6%
28,066
+15.2%
0.00%0.0%
Q3 2017$670,000
+101.8%
24,373
+93.3%
0.00%
Q2 2017$332,000
+21.2%
12,606
-4.3%
0.00%
Q1 2017$274,000
-26.7%
13,166
-27.2%
0.00%
Q4 2016$374,000
+0.8%
18,078
-21.0%
0.00%
Q3 2016$371,000
+9.8%
22,886
-7.9%
0.00%
Q2 2016$338,000
-50.7%
24,852
-36.7%
0.00%
-100.0%
Q1 2016$685,000
+19.3%
39,283
+133.7%
0.00%0.0%
Q4 2015$574,000
+33.5%
16,806
+16.2%
0.00%0.0%
Q3 2015$430,000
-63.7%
14,461
-61.0%
0.00%0.0%
Q2 2015$1,186,000
+124.2%
37,098
+45.5%
0.00%0.0%
Q1 2015$529,000
-16.4%
25,494
-31.8%
0.00%0.0%
Q4 2014$633,000
+77.3%
37,408
+102.5%
0.00%
Q3 2014$357,000
+48.8%
18,473
+161.4%
0.00%
Q2 2014$240,0007,0660.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
NovaQuest Capital Management, L.L.C. 1,558,426$48,000,00065.50%
Essex Woodlands Management, Inc. 3,842,047$118,335,00025.90%
Rhenman & Partners Asset Management AB 203,181$6,258,0000.77%
EAM Global Investors LLC 44,898$1,383,0000.72%
Fosun International Ltd 319,313$9,835,0000.62%
EAM Investors, LLC 113,096$3,483,0000.58%
ArrowMark Colorado Holdings LLC 1,735,699$53,460,0000.53%
Perceptive Advisors 618,957$19,064,0000.53%
ESSEX INVESTMENT MANAGEMENT CO LLC 111,360$3,430,0000.45%
Schonfeld Strategic Advisors LLC 83,700$2,578,0000.19%
View complete list of REVANCE THERAPEUTICS INC shareholders